NCT03065790终止不适用
Early FDG PET/CT Imaging as a Measure of Response in Patients With Non-Hodgkin Lymphoma on Lenalidomide
适应症
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 1
- 试验地点
- 1
- 主要终点
- Number of FDGmax SUV % change in FDG SUVmax
研究概览
简要总结
Adult patients with non-Hodgkin lymphoma who will be treated with lenalidomide will undergo FDG PET/CT scan as an early evaluation of response to therapy. Changes in FDG uptake will be correlated response and long term outcomes.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Adult patients, at least 18 years of age
- •History of histologically confirmed NHL as assessed per medical record review.
- •At least one site of measurable disease (per RECIST 1.1) that is seen on CT, MRI, or FDG PET/CT.
- •Recommended to start lenalidomide.
- •Participants must be informed of the investigational nature of this study and provide written informed consent in accordance with institutional and federal guidelines prior to study-specific procedures.
排除标准
- •Females who are pregnant or breast-feeding at the time of screening will not be eligible for this study. Female participants of child-bearing potential will have a urine or serum pregnancy test at the time of the screening visit.
- •Inability to tolerate imaging procedures in the opinion of the investigator or treating physician.
- •Serious or unstable medical or psychological conditions that, in the opinion of the investigator would compromise the subject's safety or successful participation in the study.
结局指标
主要结局
Number of FDGmax SUV % change in FDG SUVmax
时间窗: 2 years
次要结局
- Overall Survival(2 years)
研究者
研究点 (1)
Loading locations...
相似试验
终止
不适用
Early FDG PET in MelanomaClinical Stage III Nodal or Intransit Disease or Resectable Stage IV MelanomaNCT02716077Abramson Cancer Center at Penn Medicine6
已完成
不适用
FDG PET/CT and Directed Metabolic Core Needle Biopsy in the Management of LymphomaLymphomaNCT05186610Post Graduate Institute of Medical Education and Research, Chandigarh480
已完成
不适用
FDG-PET/MRI imaging for the evaluation of early response to nivolumab in patients with previously treated non-small cell lung cancerPreviously treated non-small cell lung cancerJPRN-UMIN000020707Third department of internal medicine, Universtiy of Fukui25
进行中（未招募）
1 期
Treatment monitoring using FDG-PET/CT and FLT-PET/CT in patients with Hodgkin Lymphoma. - PET/CT treatment monitoring in Hodgkin Lymphoma.Hodgkin LymphomaEUCTR2009-017587-16-GBBarts Health NHS Trust
Unknown
不适用
Non-invasive Evaluation of Lymphoma Patients Based on Artificial Intelligence and PET/MRINon Hodgkin LymphomaLymphomaFollicular LymphomaNCT04154228Tel-Aviv Sourasky Medical Center100